Martingale Asset Management L P Macrogenics Inc Transaction History

Martingale Asset Management L P

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$4.48 - $10.11 $3,601 - $8,128	-804 Reduced 4.94%	15,482 $148,000
Q1 2023 May 12, 2023	SELL	$4.82 - $7.24 $24 - $36	-5 Reduced 0.03%	16,286 $116,000
Q4 2022 Feb 13, 2023	BUY	$3.34 - $6.98 $5,400 - $11,286	1,617 Added 11.02%	16,291 $109,000
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $44,168 - $76,598	14,674 New	14,674 $51,000
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $145,827 - $253,578	-7,117 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$18.99 - $33.2 $135,151 - $236,284	7,117 New	7,117 $226,000
Q4 2020 Feb 10, 2021	SELL	$19.41 - $26.0 $188,606 - $252,642	-9,717 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$24.69 - $31.6 $24 - $31	1 Added 0.01%	9,717 $244,000
Q2 2020 Aug 10, 2020	BUY	$5.2 - $29.12 $50,523 - $282,929	9,716 New	9,716 $271,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.